GSK Plc

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: GB00BN7SWP63
GBP
19.36
2.39 (14.11%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

2.94 M

Shareholding (Jun 2026)

FII

0.13%

Held by 8 FIIs

DII

99.87%

Held by 1 DIIs

Promoter

0.00%

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Dashboard

Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters

Mojo Parameters

Stock DNA

stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

GBP 78,137 Million (Micro Cap)

stock-summary
P/E

11.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

258.42%

stock-summary
Debt Equity

1.08

stock-summary
Return on Equity

46.77%

stock-summary
Price to Book

4.43

Revenue and Profits:
Net Sales:
8,409 Million
(Quarterly Results - Jun 2026)
Net Profit:
553 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-7.61%
0%
-7.61%
6 Months
-6.67%
0%
-6.67%
1 Year
-15.8%
0%
-15.8%
2 Years
-3.42%
0%
-3.42%
3 Years
10.34%
0%
10.34%
4 Years
1.28%
0%
1.28%
5 Years
-9.51%
0%
-9.51%

GSK Plc for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions

News

Icon
No Recent News for the Company

Announcements stock-summary

Icon
No announcement available

Corporate Actions stock-summary

Icon
No corporate action available
stock-summaryKey Factors

Quality key factors stock-summary

Factor
Value
Sales Growth (5y)
0.22%
EBIT Growth (5y)
4.00%
EBIT to Interest (avg)
9.06
Debt to EBITDA (avg)
1.54
Net Debt to Equity (avg)
0.99
Sales to Capital Employed (avg)
0.82
Tax Ratio
10.85%
Dividend Payout Ratio
46.78%
Pledged Shares
0
Institutional Holding
0.13%
ROCE (avg)
23.82%
ROE (avg)
54.88%

Valuation key factors

Factor
Value
P/E Ratio
11
Industry P/E
Price to Book Value
4.43
EV to EBIT
11.77
EV to EBITDA
8.46
EV to Capital Employed
2.83
EV to Sales
2.89
PEG Ratio
0.21
Dividend Yield
255.59%
ROCE (Latest)
24.02%
ROE (Latest)
41.25%

Technicals key factors

Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Mildly Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bearish
Mildly Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Jun 2026stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Foreign Institutions

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 8 Foreign Institutions (0.13%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'26 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2026 is 10.22% vs -11.48% in Mar 2026",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2026 is -69.93% vs 152.96% in Mar 2026",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'26",
        "Mar'26",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "8,409.00",
          "val2": "7,629.00",
          "chgp": "10.22%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "2,621.00",
          "val2": "2,616.00",
          "chgp": "0.19%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "182.00",
          "val2": "167.00",
          "chgp": "8.98%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-2,409.00",
          "val2": "-210.00",
          "chgp": "-1,047.14%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "553.00",
          "val2": "1,839.00",
          "chgp": "-69.93%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "285.20%",
          "val2": "282.20%",
          "chgp": "0.30%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 4.11% vs 3.46% in Dec 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is 113.11% vs -44.40% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "32,667.00",
          "val2": "31,376.00",
          "chgp": "4.11%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "10,532.00",
          "val2": "8,213.00",
          "chgp": "28.24%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "667.00",
          "val2": "644.00",
          "chgp": "3.57%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-1,601.00",
          "val2": "-2,469.00",
          "chgp": "35.16%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "6,289.00",
          "val2": "2,951.00",
          "chgp": "113.11%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "251.60%",
          "val2": "180.50%",
          "chgp": "7.11%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'26 - QoQstock-summary

Jun'26
Mar'26
Change(%)
Net Sales
8,409.00
7,629.00
10.22%
Operating Profit (PBDIT) excl Other Income
2,621.00
2,616.00
0.19%
Interest
182.00
167.00
8.98%
Exceptional Items
-2,409.00
-210.00
-1,047.14%
Consolidate Net Profit
553.00
1,839.00
-69.93%
Operating Profit Margin (Excl OI)
285.20%
282.20%
0.30%
USD in Million.
Direction Arrows
Net Sales

QoQ Growth in quarter ended Jun 2026 is 10.22% vs -11.48% in Mar 2026

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2026 is -69.93% vs 152.96% in Mar 2026

Annual Results Snapshot (Consolidated) - Dec'25stock-summary

Dec'25
Dec'24
Change(%)
Net Sales
32,667.00
31,376.00
4.11%
Operating Profit (PBDIT) excl Other Income
10,532.00
8,213.00
28.24%
Interest
667.00
644.00
3.57%
Exceptional Items
-1,601.00
-2,469.00
35.16%
Consolidate Net Profit
6,289.00
2,951.00
113.11%
Operating Profit Margin (Excl OI)
251.60%
180.50%
7.11%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2025 is 4.11% vs 3.46% in Dec 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2025 is 113.11% vs -44.40% in Dec 2024

stock-summaryCompany CV
About GSK Plc stock-summary
stock-summary
GSK Plc
Pharmaceuticals & Biotechnology
GlaxoSmithKline PLC is a global healthcare company. The Company operates through two segments: Pharmaceuticals and Vaccines. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases. The Company makes a range of prescription medicines and vaccines products. The Pharmaceuticals business discovers, develops and commercializes medicines to treat a range of acute and chronic diseases. The Vaccines business provides vaccines for people of all ages from babies and adolescents to adults and older people. It has a portfolio of medicines in respiratory and HIV. Its Pharmaceuticals business includes Respiratory, HIV, Specialty products, and Classic and Established products. Its Vaccines business has a portfolio of over 40 pediatric, adolescent, adult, older people and travel vaccines.
Company Coordinates stock-summary
Company Details
G S K House, 980 Great West Road , BRENTFORD None : TW8 9GS
stock-summary
Tel: 44 20 80475000
stock-summary
Registrar Details